Johnson & Johnson Says Lung Cancer Drug Combination Extends Median Survival to Over 34 Months
MT Newswires Live
Yesterday
Johnson & Johnson (JNJ) said Sunday a Phase 3 trial of its lung cancer drug Rybrevant combined with chemotherapy resulted in a median overall survival of 34.3 months.
The treatment combination extended patient survival by more than six months compared to the 27.9-month median observed in the standalone chemotherapy group, the company said.
An analysis adjusting for trial participants who switched to the experimental therapy after their disease progressed demonstrated a 43% lower risk of death, it said.
The most common side effects from the treatment included paronychia, neutropenia, and rash, Johnson & Johnson said.
Shares of the company were up over 1% in Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.